DEHYDROGENASE CRYSTALS AS CATALYST IN ORGANIC SYNTHESIS

Information

  • Research Project
  • 2392221
  • ApplicationId
    2392221
  • Core Project Number
    R44GM051781
  • Full Project Number
    5R44GM051781-03
  • Serial Number
    51781
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/15/1994 - 29 years ago
  • Project End Date
    3/31/1998 - 26 years ago
  • Program Officer Name
  • Budget Start Date
    4/1/1997 - 27 years ago
  • Budget End Date
    3/31/1998 - 26 years ago
  • Fiscal Year
    1997
  • Support Year
    3
  • Suffix
  • Award Notice Date
    4/21/1997 - 27 years ago

DEHYDROGENASE CRYSTALS AS CATALYST IN ORGANIC SYNTHESIS

Cross-Linked Enzyme Crystals (CLECs) exhibit remarkable characteristics, that makes them extremely useful in organic synthesis in general and in the synthesis of optically pure compounds in particular. CLEC formulation has been limited to hydrolases, although commercial interest in more complex enzymes such as cofactor dependent dehydrogenases is high. In Phase I, using alcohol dehydrogenase as a prototype, we demonstrated that a cross-linked crystalline enzyme/cofactor complex is catalytically active, that the enzyme is stabilized to organic solvent, thermal, and proteolytic inactivation, and that the cofactor can be repeatedly regenerated while remaining tightly bound to the apoenzyme. In Phase II, we will continue development of CLECs of horse liver alcohol dehydrogenase and a thermostable microbial alcohol dehydrogenase, and begin development of L-lactate dehydrogenase and L-leucine dehydrogenase CLECs. CLEC formulation; including enzyme purification, crystallization, cross-linking and drying, will be scaled to the 100 gram level. The stability, substrate specificity, and performance of the dehydrogenase CLECS in reactions of commercial interest will be studied. PROPOSED COMMERCIAL APPLICATION: Alcohol dehydrogenases from various sources have a great potential in preparative organic synthesis as they have a broad substrate specificity and can produce valuable chiral building blocks in high optical purity. ADH-CLECs may become major catalysts in the synthesis of optically pure drugs. The market represents one of the fastest growing sectors of the pharmaceutical industry and is expected to reach $40 billion by the end of the century.

IC Name
NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
  • Activity
    R44
  • Administering IC
    GM
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    821
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    ZRG7
  • Study Section Name
  • Organization Name
    ALTUS PHARMACEUTICALS, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    CAMBRIDGE
  • Organization State
    MA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    021394807
  • Organization District
    UNITED STATES